Jonathan M. Lee

Skadden

Partner, New York

Mergers and Acquisitions

T: 212.735.3454
jonathan.lee@skadden.com

Education

J.D., Georgetown University Law Center, 2016 (*magna cum laude*; Order of the Coif; Managing Editor, *The Georgetown Law Journal*)

M.S., Georgetown University, 2012

B.A., Cornell University, 2011

Bar Admissions

New York

Jonathan M. Lee focuses on mergers and acquisitions, corporate governance, securities and general corporate law matters. Mr. Lee regularly advises public and private companies in a variety of U.S. and cross-border transactions, including acquisitions, dispositions, auctions, carve-outs, business separations, investments, financings, restructurings, financial advisor engagements and SPAC transactions. In recognition of his work, Mr. Lee has been named to Lawdragon's 500 X — The Next Generation list and repeatedly honored as one of *Best Lawyers*' Ones To Watch in America.

Selected representations by Mr. Lee include:

- DuPont de Nemours, Inc. in various transactions, including its:
  - announced intent to spin off its electronics business
  - pending $1.825 billion sale of its aramids business (Kevlar and Nomex) to Arclin, a portfolio company of funds managed by The Jordan Company
- International Flavors & Fragrances Inc. in the $810 million sale of its cosmetic ingredients business to Clariant AG
- Molina Healthcare, Inc. in its $350 million acquisition of ConnectiCare, a leading health plan in the state of Connecticut
- the CEO of Radius Global Infrastructure, Inc. in the company's $3 billion acquisition by EQT Active Core Infrastructure and Public Sector Pension Investment Board
- SMS Assist, L.L.C. in its $950 million merger with Lessen Inc.
- Theravance Biopharma in the $1.5 billion sale of its interests in Theravance Royalty Company LLC, representing its TRELEGY ELLIPTA royalty interests, to Royalty Pharma plc and related $40 million investment in Theravance Biopharma's ampreloxetine program
- Red Hat, Inc. in its $34 billion acquisition by IBM
- Express Scripts Holding Company in its $67 billion acquisition by Cigna Corporation
- Danaher Corporation in its acquisition of InSilixa, Inc.
- Orum Therapeutics, Inc. in the $180 million sale of its ORM-6151 program to Bristol-Myers Squibb Company
- FaZe Clan Inc. in its $1 billion merger with B. Riley Principal 150 Merger Corp.
- Aspirational Consumer Lifestyle Corp. in its $2.1 billion merger with Wheels Up Partners Holdings LLC
- Social Capital Hedosophia in its $3.7 billion merger with Clover Health Investments, Corp.
- AP WIP Investments Holdings in its $860 million acquisition by Landscape Acquisition Holdings
- CPI International, Inc. (previously a portfolio company of Veritas Capital and now a portfolio company of Odyssey Investment Partners) in its:
  - acquisition of SATCOM Technologies, the antenna systems business of General Dynamics Mission Systems
  - disposition of ASC Signal Holdings Corporation to Kratos Defense & Security Solutions, Inc.

- Veritas Capital and certain of its portfolio companies in various transactions and corporate matters, including Verscend Technologies, Inc. (n/k/a Cotiviti, Inc., a portfolio company of Veritas Capital) in its $4.9 billion acquisition of Cotiviti Holdings, Inc.
- Rite Aid Corporation in various transactions and corporate matters, including its:
  - $4.4 billion sale of 1,932 stores and related assets to Walgreens Boots Alliance, Inc.
  - proposed (but terminated) merger with Albertsons Companies, Inc.
- Mars, Incorporated in various transactions and corporate matters
- Goldman Sachs & Co. LLC as financial advisor in various transactions, including to:
  - Cameco Corporation in connection with its and Brookfield Renewable Partners' strategic partnership's $7.9 billion acquisition of Westinghouse Electric Company
  - Signify Health, Inc. in its $8 billion acquisition by CVS Pharmacy, Inc.
- Centerview Partners LLC as financial advisor in various transactions, including to:
  - Cerevel Therapeutics Holdings, Inc. in its $8.7 billion acquisition by AbbVie Inc.
  - Inhibrx, Inc. in its $2.2 billion sale of INBRX-101 to Sanofi
  - G1 Therapeutics, Inc. in its $405 million acquisition by Pharmacosmos A/S

Mr. Lee is actively involved in Skadden's training and recruiting programs.